Possible Reason for the Failure of Immunotherapy in Glioblastoma

It is seen that the majority of both primary and recurrent tumors have a low density of TILs. While all the cases of tumors have CD3+ TILs. A significantly higher CD8+ TIL density was demonstrated by quantitative analysis of TILs at recurrence.

Moreover, between primary and recurrent groups, there was no difference observed in CD3+, CD4+ and PD-1+ TIL density. Treatment target like anti-PD-1 antibodies with immune checkpoint inhibition, blocks PD-1/PD-L1 interactions. This restores the effector T cell proliferation and function.

Immunotherapy in Glioblastoma

In a specific type of cancer – melanoma, it was seen that response to anti-PD-1 immunotherapy is associated with a higher density of CD8+ TILs. However, earlier clinical trials that have been conducted using anti-PD-1 immunotherapy in glioblastoma, demonstrated limited success.

Studies like the CheckMate 143 trial and similar ones demonstrated no significant overall survival benefit in recurrent glioblastoma with anti-PD-1 when compared to the anti-angiogenic drug bevacizumab.

However, another study (Cloughesy et a) states that anti-PD-1 therapy significantly increases the overall survival if given before and after recurrent tumor resection than only after recurrent surgery.

“The level of T cell infiltration seen in this small cohort of matched primary and recurrent glioblastoma tissue was low. Though the number of CD8+ TILs was significantly higher in recurrent compared to primary tumours, overall TIL density at recurrence was still mild. PD-1+ TILs in particular were absent in the majority of our cases. Whether this is why many clinical trials using anti-PD-1 immunotherapy have not shown significant survival benefit in glioblastoma requires further investigation,” say the Tooney Research Team.

Source: Medindia

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.